Study of the mutational landscape of primary foci and metastases of papillary carcinoma in the BRAF, KRAS and EGFR genes, their relationship with the clinical characteristics of the tumor
- 作者: Asanova E.R.1, Maksimova P.E.1,2, Zima D.V.1, Khabarov O.R.1, Fedotov V.V.1, Zyablitskaya E.Y.1
-
隶属关系:
- FSAEI HE “V.I. Vernadsky Crimean Federal University”
- FSFEI HE Pavlov First St. Petersburg State Medical University
- 期: 卷 23, 编号 2 (2025)
- 页面: 71-76
- 栏目: Original research
- URL: https://ogarev-online.ru/1728-2918/article/view/293276
- DOI: https://doi.org/10.29296/24999490-2025-02-09
- ID: 293276
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Introduction. Due to the rapidly growing incidence of tumor pathology of the thyroid gland, the range of molecular genetic research methods used to study the targets of targeted drugs, prognosis and surgical tactics is growing.
Aim. To study the frequency of mutations of the BRAF, KRAS, EGFR genes in neoplastic diseases of the thyroid gland, their relationship with Bethesda categories at the preoperative stage, invasion and the presence of metastases.
Methods. The material was taken from FFPE blocks of the thyroid glands of operated patients. DNA analysis was carried out on 73 histologically verified samples: 53 with papillary carcinoma (11 of them – follicular variant, 42 – classic), 16 – with follicular adenoma, 4 – with autoimmune thyroiditis. We used DNA extraction and real-time PCR with Test-Gen reagents, Russia. Comparisons were made using the Pearson chi-square test.
Results. In the classic variant of papillary carcinoma, the BRAF V600E mutation is more often detected; in the follicular variant of papillary carcinoma, the following mutations are identified: BRAF, and more often BRAF V600K, as well as EGFR, KRAS. In follicular adenoma, mutations were found only in the KRAS gene. In most cases, the BRAF V600E mutation was found in patients with the classic variant of papillary carcinoma, having a Bethesda VI category at the preoperative stage. The BRAF V600K mutation is also more common among patients with Bethesda category VI, and the absence of this mutation is associated with female gender and lack of tumor vascular invasion. When analyzing the status of genes in primary tumors and metastases, discordance in the BRAF gene was revealed, which indicates the possible development of such clonal evolution of the tumor.
Conclusion. The ability to identify key genes involved in the development of oncotransformation of the thyroid epithelium is promising and contributes to personalization and selection of drugs that affect oncogenesis.
关键词
作者简介
Elvina Asanova
FSAEI HE “V.I. Vernadsky Crimean Federal University”
编辑信件的主要联系方式.
Email: elyabiolog@yandex.ru
ORCID iD: 0009-0001-0409-3297
Order of the Red Banner of Labor, S.I. Georgievsky Medical Institute, Junior Scientific Worker
俄罗斯联邦, blvd Lenin 5/7, Simferopol, 295001Polina Maksimova
FSAEI HE “V.I. Vernadsky Crimean Federal University”; FSFEI HE Pavlov First St. Petersburg State Medical University
Email: pmaksq@mail.ru
ORCID iD: 0000-0001-5920-8664
Order of the Red Banner of Labor, S.I. Georgievsky Medical Institute, junior scientific worker Central Research Laboratory, Resident doctor specializing in hematology
俄罗斯联邦, blvd Lenin 5/7, Simferopol, 295001; L'va Tolstogo str. 6–8, St. Petersburg, 197022Dmitry Zima
FSAEI HE “V.I. Vernadsky Crimean Federal University”
Email: dmitrii_zima@mail.ru
ORCID iD: 0000-0003-4732-0311
Saint Luke’s multidisciplinary Clinical Hospital, surgeon, Candidate of Medical Sciences
俄罗斯联邦, blvd Lenin 5/7, Simferopol, 295001Oleg Khabarov
FSAEI HE “V.I. Vernadsky Crimean Federal University”
Email: khabar.68@mail.ru
ORCID iD: 0000-0001-7795-5882
Order of the Red Banner of Labor, S.I. Georgievsky Medical Institute, surgeon, assistant department of multidisciplinary clinical training
俄罗斯联邦, blvd Lenin 5/7, Simferopol, 295001Vasily Fedotov
FSAEI HE “V.I. Vernadsky Crimean Federal University”
Email: v.v.fedotoff@yandex.ru
ORCID iD: 0000-0002-9447-3292
Order of the Red Banner of Labor, S.I. Georgievsky Medical Institute, pathologist Department of Pathomorphology and Molecular Oncology of the Central Research Laboratory
俄罗斯联邦, blvd Lenin 5/7, Simferopol, 295001Evgenia Zyablitskaya
FSAEI HE “V.I. Vernadsky Crimean Federal University”
Email: evgu79@mail.ru
ORCID iD: 0000-0001-8216-4196
Order of the Red Banner of Labor, S.I. Georgievsky Medical Institute, leading scientific worker Central Research Laboratory, Doctor of Medical Sciences, Professor
俄罗斯联邦, blvd Lenin 5/7, Simferopol, 295001参考
- Brent G.A. Mechanisms of thyroid hormone action. J. Clin. Invest. 2012; 122 (9): 3035–43. doi: 10.1172/JCI60047
- Kostopoulou E., Miliordos K., Spiliotis B. Genetics of primary congenital hypothyroidism-a review. Hormones (Athens). 2021; 20 (2): 225–36. doi: 10.1007/s42000-020-00267-x
- Hegedüs, L. The Thyroid Nodule. New England J. of Medicine. 2004; 351 (17): 1764–71. doi: 10.1056/nejmcp031436
- Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Blondal T., Geller F., Jakobsdottir M., Magnusdottir D.N., Matthiasdottir S., Stacey S.N., Skarphedinsson O.B., Helgadottir H., Li W., Nagy R., Aguillo E., Faure E., Prats E., Saez B., Martinez M., Eyjolfsson G.I., Bjornsdottir U.S., Holm H., Kristjansson K., Frigge M.L., Kristvinsson H., Gulcher J.R., Jonsson T., Rafnar T., Hjartarsson H., Mayordomo J.I., de la Chapelle A., Hrafnkelsson J., Thorsteinsdottir U., Kong A., Stefansson K. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet. 2009; 41 (4): 460–4. doi: 10.1038/ng.339
- Cooper D.S., Biondi B. Subclinical thyroid disease. Lancet. 2012; 379 (9821): 1142–54. doi: 10.1016/S0140-6736(11)60276-6
- Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13 (3): 184–99. doi: 10.1038/nrc3431
- Nikiforov Y.E. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011; 135 (5): 569–77. doi: 10.5858/2010-0664-RAIR
- Seib C.D., Sosa J.A. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol Metab Clin North Am. 2019; 48 (1): 23–35. doi: 10.1016/j.ecl.2018.10.002
- Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W. 2nd, Tallini G., Kroll T.G., Nikiforov Y.E. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol Metab. 2003; 88 (5): 2318–26. doi: 10.1210/jc.2002-021907. PMID: 12727991
- Kim S., Lee K.E., Myong J.P., Park J., Kim M. H. EGFR gene copy number and protein expression in papillary thyroid carcinoma: Correlation with clinicopathologic features and behavior of tumor. Annals of Surgical Oncology, 2015; 22 (1): 273–9. doi: 10.1245/s10434-014-3760-8
- Bikas A., Vachhani S., Jensen K., Vasko V., Burman K.D. Targeted therapies in thyroid cancer: an extensive review of the literature. Expert Rev Clin Pharmacol. 2016; 9 (10): 1299–313. doi: 10.1080/17512433.2016.1204230
- Lee J.H., Lee E.S., Kim Y.S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007; 110 (1): 38–46. doi: 10.1002/cncr.22754
- Tufano R.P., Teixeira G.V., Bishop J., Carson K.A., Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2012; 91 (5): 274–86. doi: 10.1097/MD.0b013e31826a9c71
- Bal C., Ballal S. Is There Any True Association Between BRAF V600E Mutation and Recurrence, Particularly in Low-Risk, Papillary Thyroid Cancer? J. Clin. Oncol. 2015; 33 (22): 2481. doi: 10.1200/JCO.2014.60.0999
- Czarniecka A., Oczko-Wojciechowska M., Barczyński M. BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 2016; 5 (5): 495–505. doi: 10.21037/gs.2016.09.09
- Долгов В.В., Шабалова И.П., Селиванова А.В. Лабораторная диагностика заболеваний щитовидной железы. Иммунохимические, иммуноцитохимические, молекулярно-генетические исследования, атлас традиционной и жидкостной цитологии, клиническая интерпретация лабораторных данных. Триада, 2022; 288. [Dolgov V.V., Shabalova I.P., Selivanova A.V. Laboratory diagnosis of thyroid diseases. Immunochemical, immunocytochemical, molecular genetic studies, atlas of traditional and liquid-based cytology, clinical interpretation of laboratory data. Triada, 2022; 288 (in Russian)]
- Федянин М.Ю., Эльснукаева Х.Х., Тюляндин С.А. Внутриопухолевая гетерогенность и клональная эволюция рака толстой кишки. Успехи молекулярной онкологии. 2017; 4 (1): 24–34. [Fedyanin M.Yu., Elsnukaeva H.H., Tjulandin S.A. Heterogeneity and clonal evolution of colorectal cancer. Advances in Molecular Oncology. 2017; 4 (1): 24–34 (In Russian)]
补充文件
